Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015

PloS One
Seung Yeon SongEun Young Kim

Abstract

To investigate the impact of national implementation of age restriction on fluoroquinolone prescription in children and adolescents. Data collected from the database of Health Insurance Review and Assessment Service in South Korea, a national health insurance system to analyze fluoroquinolone prescribing practice in children and adolescents younger than 18 years, between 2007 and 2015. The age restriction was implemented in December 2009. The annual prescription rate of FQ per 100,000 person-years was calculated and an autoregressive model was used to predict the prescription pattern if an intervention had not occurred. A total of 505,859 children received systemic fluoroquinolone during the study period-297,054 ciprofloxacin, and 208,805 levofloxacin. After implementation of the drug utilization review program, the annual prescription rate for ciprofloxacin declined by 97.5% (from 840 to 21 per 100,000 person-years, P < 0.001), and for levofloxacin by 96.4% (from 598 to 11 per 100,000 person-years, P < 0.001). The decline was more dramatic in the outpatient setting than in the inpatient setting for both drugs. The dramatic and sustained decline in prescription number and change in prescription pattern after the regulatory acti...Continue Reading

References

Dec 24, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J E BurkhardtU B Schaad
Jun 19, 2002·JAMA : the Journal of the American Medical Association·Joseph F PerzMarie R Griffin
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Melinda M NeuhauserJohn P Quinn
Jun 5, 2003·Pediatrics·Martin ChalumeauUNKNOWN Pediatric Fluoroquinolone Safety Study Investigators
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
Dec 23, 2003·The Pediatric Infectious Disease Journal·Richard Grady
Jan 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald E Low
Feb 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael A RubinMatthew H Samore
Jul 20, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Conan MacDougallRonald E Polk
Mar 3, 2006·The Pediatric Infectious Disease Journal·Vishakha Sabharwal, Colin D Marchant
Aug 22, 2006·The Journal of Antimicrobial Chemotherapy·Fawziah MarraWilliam R Bowie
Sep 5, 2006·Pediatrics·UNKNOWN Committee on Infectious Diseases
Sep 30, 2006·The Lancet Infectious Diseases·Ari RobicsekDavid C Hooper
Aug 31, 2007·Pediatric Annals·Thomas S Murray, Robert S Baltimore
Oct 18, 2007·JAMA : the Journal of the American Medical Association·Michael E Pichichero, Janet R Casey
Jun 10, 2010·European Journal of Clinical Pharmacology·Alessandro PortaNicola Principi
Jul 28, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Karl WeissMichel Gaudet
Sep 29, 2011·Pediatrics·John S BradleyUNKNOWN American Academy of Pediatrics
Nov 9, 2011·Pediatrics·Adam L HershSamir S Shah
Apr 5, 2012·Clinical Pharmacology and Therapeutics·E Kimland, V Odlind
May 29, 2013·BMC Infectious Diseases·Zhi-Tao YangOlivier Lortholary
Jun 7, 2013·Korean journal of pediatrics·Soo-Han ChoiYae-Jean Kim
Jun 13, 2013·JAMA : the Journal of the American Medical Association·Jeffrey S GerberTheoklis E Zaoutis
Jun 13, 2013·JAMA : the Journal of the American Medical Association·Jonathan A Finkelstein
Aug 6, 2013·International Journal of Medical Informatics·Ji Haeng HeoEui-Kyung Lee
Jul 27, 2014·The Journal of Antimicrobial Chemotherapy·Victoire de LastoursBruno Fantin
Aug 16, 2014·Pharmacoepidemiology and Drug Safety·Ju-Young ShinByung-Joo Park
Aug 28, 2014·International Journal of Clinical Pharmacology and Therapeutics·Mathieu GenuiniMathie Lorrot
Oct 16, 2014·JAMA : the Journal of the American Medical Association·Jeffrey S GerberTheoklis E Zaoutis
Mar 3, 2015·International Journal of Antimicrobial Agents·Nicola Principi, Susanna Esposito
Dec 26, 2016·The Journal of Pediatrics·Ilan YoungsterSeoyoung C Kim

❮ Previous
Next ❯

Software Mentioned

DUR
SAS

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

© 2022 Meta ULC. All rights reserved